Form 8-K - Current report:
SEC Accession No. 0001493152-23-020001
Filing Date
2023-06-02
Accepted
2023-06-02 17:00:46
Documents
15
Period of Report
2023-05-30
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46686
2 ex16-1.htm EX-16.1 1133
3 ex16-1_001.jpg GRAPHIC 106197
  Complete submission text file 0001493152-23-020001.txt   426207

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bfri-20230530.xsd EX-101.SCH 4288
5 XBRL DEFINITION FILE bfri-20230530_def.xml EX-101.DEF 27600
6 XBRL LABEL FILE bfri-20230530_lab.xml EX-101.LAB 38253
7 XBRL PRESENTATION FILE bfri-20230530_pre.xml EX-101.PRE 26217
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6875
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 23989919
SIC: 2834 Pharmaceutical Preparations